玻璃酸钠关节腔注射对膝骨关节炎患者关节液及血浆中白介素—17的影响

2017-08-26 11:22:44白玉明张海森刘畅
中国医药导报 2017年19期
关键词:骨关节炎血浆研究

白玉明 张海森 刘畅

[摘要] 目的 探讨膝骨性关节炎(OA)患者采用玻璃酸钠关节腔注射治疗后血浆和关节滑液中白介素(IL)-17的水平变化。 方法 选择2013年1月~2016年1月因膝关节OA于沧州市中心医院行玻璃酸钠关节腔注射治疗的56例患者作为研究对象(试验组),以30例膝关节正常的自愿者作为正常对照(对照组)。两组研究对象性别、年龄、体重指数比较差异均无统计学意义(P > 0.05)。试验组采用视觉模拟疼痛评分(VAS)评价膝关节疼痛程度。玻璃酸钠关节腔注射之前及注射治疗之后1、4、8、12周抽取肘部静脉血液及患侧膝关节滑液,采用ELISA检测试剂盒测量血浆及关节滑液IL-17含量。对照组抽取肘部静脉血进行相应检测并比较。 结果 試验组玻璃酸钠关节腔注射治疗后8周内各时间点VAS评分均较治疗前显著降低(P < 0.05),但治疗后12周与治疗前比较VAS评分差异无统计学意义(P > 0.05)。对照组血浆IL-17含量为(2.4±1.7)pg/mL。与对照组比较,试验组玻璃酸钠治疗前浆IL-17含量显著增高(P < 0.05);试验组患者玻璃酸钠注射治疗后8周内各时间点IL-17含量均较治疗前显著降低(P < 0.05),但血浆IL-17含量仍高于对照组水平(P < 0.05),治疗后12周与治疗前比较IL-17含量差异无统计学意义(P > 0.05)。 结论 玻璃酸钠关节腔注射治疗可在治疗后8周内显著改善膝关节OA患者的疼痛症状,并可在一定程度上降低患者体内IL-17水平,但治疗后12周临床疗效基本消失,体内IL-17水平也恢复至治疗前水平。

[关键词] 玻璃酸钠;骨关节炎;膝;白介素-17

[中图分类号] R683 [文献标识码] A [文章编号] 1673-7210(2017)07(a)-0118-04

[Abstract] Objective To discuss the changes of interleukin-17 (IL-17) levels in both synovial fluid and plasm of patients with primary knee osteoarthritis (OA) after intra-articular injection of Sodium Hyaluronate. Methods 56 patients with primary knee OA given intra-articular injection of Sodium Hyaluronate in Central Hospital of Cangzhou from January 2013 to January 2016 (experimental group) and 30 healthy individuals (control group) were recruited into the study. There were no significant differences in gender, age, and body mass index between the two groups (P > 0.05). Visual analogue scale (VAS) was used to evaluate the pain level of the patients. The IL-17 concentrations in both plasma and synovial fluid were measured before intra-articular injection of Sodium Hyaluronate and at 1, 4, 8, 12 weeks after injection in the experimental group. The IL-17 levels in plasma were measured in the control group. The IL-17 levels were determined using ELISA method. Results Average VAS scores within 8 weeks after the injection were substantially lower than pre-injection periods (P < 0.05) in the experimental group. Average VAS pain score at 12 weeks after intra-articular injection of Sodium Hyaluronate was not statistically significant in comparison with pre-injection period (P > 0.05). Average plasm IL-17 concentration in the control group was (2.4±1.7) pg/mL. OA patients before the injection had higher plasma IL-17 concentration compared to the control group (P < 0.05). Average IL-17 levels in both synovial fluid and plasm at each time point for patients with OA within 8 weeks after the injection were significant lower than pre-injection periods (P < 0.05), but IL-17 levels in plasma were higher than controls (P < 0.05). Average IL-17 levels in both synovial fluid and plasm at 12 weeks after the injection were not statistically significant in comparison with pre-injection periods (P > 0.05). Conclusion For the patients with knee OA, pain symptoms have significantly been improved and IL-17 levels in both synovial fluid and plasm reduced within 8 weeks after intra-articular injection of Sodium Hyaluronate. After 12 weeks, the clinical curative effect has disappearenced, IL-17 levels in both synovial fluid and plasm are restored to the level before treatment.

[Key words] Sodium Hyaluronate; Osteoarthritis; Knee; Interleukin-17

骨关节炎(osteoarthritis,OA)是一种复杂的关节滑膜及关节软骨炎性疾病[1],由于炎性细胞因子破坏了软骨细胞的合成与分解代谢平衡,进而在OA发生与发展中起重要作用[2-3]。最近研究表明,白介素-17(interleukin-17,IL-17)基因多态性与OA的易感性相关[4],膝骨关节炎患者血浆及关节炎滑液中IL-17水平高于健康人[5-6]。

登录APP查看全文

猜你喜欢
骨关节炎血浆研究
糖尿病早期认知功能障碍与血浆P-tau217相关性研究进展
FMS与YBT相关性的实证研究
抗抑郁药帕罗西汀或可用于治疗骨关节炎
中老年保健(2021年5期)2021-12-02 15:48:21
辽代千人邑研究述论
血浆置换加双重血浆分子吸附对自身免疫性肝炎合并肝衰竭的细胞因子的影响
膝骨关节炎如何防护?
基层中医药(2021年9期)2021-06-05 07:14:14
视错觉在平面设计中的应用与研究
科技传播(2019年22期)2020-01-14 03:06:54
EMA伺服控制系统研究
CHF患者血浆NT-proBNP、UA和hs-CRP的变化及其临床意义
海南医学(2016年8期)2016-06-08 05:43:00
脑卒中后中枢性疼痛相关血浆氨基酸筛选